/

VTVT

vTv Therapeutics Inc.Closed

28.23−2.23 −7.32%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

31.00

Prev close

30.46

Day range

27.8731.22

52-week range

19.5044.00

Volume

41.08K0.61×

Mkt cap

111.62M

P/E ttm

—

Fwd P/E

-6.00

EPS ttm

-0.6600

Div yield

0.00%

Earnings

—

From 52w high

−35.84%

Price Chart

Yahoo Finance · delayed

VTVTOct 13, 2026O 30.75H 31.22L 27.87C 28.23−2.23 (−7.32%)Vol 41.80K

SMA 5031.87
SMA 20034.32

1Y change +29.47% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VTVT vTv Therapeutics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.99%
1 month: −11.70%
3 months: −11.45%
6 months: −26.35%
Year to date: −29.41%
1 year: +29.47%

Valuation & ownership

Market cap: 111.62M
Enterprise value: 264.10M
P/E (ttm): —
Forward P/E: -6.00
PEG ratio: —
Price / book: 4.46
Price / sales (ttm): 3.03
EV / EBITDA: -28.57
EPS (ttm): -0.6600
EPS (forward): -4.70
Beta (5y monthly): 0.21
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 3.95M
Float: 2.16M
Short % of float: 6.53%
Short ratio (days): 3.66
Held by insiders: 38.83%
Held by institutions: 42.60%
Avg volume (3m): 67.20K
50-day average: 31.96
200-day average: 34.37
52-week change: +29.47%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 36.6
vs 50-day SMA: −11.43%
vs 200-day SMA: −17.76%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.15%
Realised vol (20d, ann.): 45.1%
From 52-week high: −35.84%
From 52-week low: +44.77%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

54.71

+93.82% implied

Low 42.00Median 57.00High 67.00

Recommendation trend

Now7 / 0 / 0
1m ago7 / 0 / 0
2m ago

DES

About vTv Therapeutics Inc.

Yahoo Finance profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

Sector: Healthcare
Industry: Biotechnology
Employees: 26
Headquarters: High Point, NC, United States
Website: vtvtherapeutics.com
Officers: Mr. Paul J. Sekhri CEO, President & Chairman of the Board
Dr. Michael Steven Tung M.B.A., M.D. Executive VP & CFO
Mr. Barry K. Brown Chief Accounting Officer
Dr. Carmen Valcarce Ph.D. Chief Scientific Officer & Executive VP

SEAS

Seasonality · VTVT

2015–2026 · monthly returns

Strongest month Oct +17.19%Weakest month Mar −8.49%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-11.5	7.8	3.9	-18.7	3.4	12.9	-14.1	-1.1	-3.6	-8.5			−29.4%
2025	17.2	21.4	-11.9	15.2	-20.4	-5.6	-0.3	8.6	43.8	-6.9	22.8	49.8	+189.6%
2024	-26.9	108.7	34.1	18.6	-16.4	-24.3	-17.9	8.3	-13.7	1.1	17.0	-13.9	+20.1%
2023	43.3	-14.7	-0.2	-4.7	2.6	-6.3	-8.6	-24.6	-6.3	-12.8	-14.3	-19.5	−56.6%
2022	-27.9	14.2	-11.8	-4.4	-20.1	36.1	20.0	17.8	-8.5	-10.9	-4.6	-19.5	−33.4%
2021	9.7	30.4	6.0	-9.2	-3.9	-7.3	-15.8	-2.6	-18.2	-6.5	-13.3	-19.8	−46.5%
2020	30.0	54.8	-44.2	9.9	37.1	-21.9	4.4	-11.5	-14.9	-4.0	22.4	-10.6	+9.4%
2019	8.3	-17.4	-27.8	-12.3	22.0	-21.9	-2.1	-6.5	18.4	-4.5	0.7	14.1	−35.8%
2018	29.1	-27.2	-28.0	-56.0	-0.6	-13.5	-18.2	-13.5	-29.4	240.3	-35.5	56.8	−55.9%
2017	18.8	5.1	8.6	-15.9	-9.6	-0.2	-12.3	24.5	10.1	5.7	-33.7	43.4	+24.4%
2016	6.5	-21.2	-9.6	22.1	-5.4	-2.7	-2.4	-0.2	27.3	-25.0	-3.2	-7.5	−29.1%
2015								-12.8	-25.2	12.6	-7.5	0.3	−31.9%

INSD

Insider Activity · VTVT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 21, 2025	Akkaraju SrinivasDirector	Stock Award(Grant) at price 22.17 per share.	106K	$2.35M
Sep 2, 2025	Baker Bros Advisors, L.P.Unknown	Stock Award(Grant) at price 0.00 per share.	51K	—

13F

Investors Holding VTVT

latest 13F filings of 29 followed managers

Investors holding VTVT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$657.1K	0.00%	17.45K	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

VTVT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VTVT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About vTv Therapeutics Inc.

Seasonality · VTVT

Insider Activity · VTVT

Congress Trades · VTVT

Investors Holding VTVT

Investors Holding VTVT

Congress Trades · VTVT

Insider Activity · VTVT

Seasonality · VTVT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About vTv Therapeutics Inc.

Financial Snapshot

Earnings & Dividends

News